ID   MD2L2_HUMAN             Reviewed;         211 AA.
AC   Q9UI95; B3KNE3; Q5TGW7; Q9UNA7; Q9Y6I6;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   18-JUN-2025, entry version 196.
DE   RecName: Full=Mitotic spindle assembly checkpoint protein MAD2B;
DE   AltName: Full=Mitotic arrest deficient 2-like protein 2;
DE            Short=MAD2-like protein 2;
DE   AltName: Full=REV7 homolog;
DE            Short=hREV7;
GN   Name=MAD2L2; Synonyms=MAD2B, REV7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH ADAM9.
RX   PubMed=10527948; DOI=10.1042/bj3430673;
RA   Nelson K.K., Schlondorff J., Blobel C.P.;
RT   "Evidence for an interaction of the metalloprotease-disintegrin tumour
RT   necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2
RT   (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-
RT   related protein, MAD2-beta.";
RL   Biochem. J. 343:673-680(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Hirota T., Nakamura H., Tada K., Marumoto T., Saya H.;
RT   "Identification of a novel human homolog of the MAD2 protein that interacts
RT   with the h-warts protein.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10366450; DOI=10.1006/geno.1999.5831;
RA   Cahill D.P., da Costa L.T., Carson-Walter E.B., Kinzler K.W.,
RA   Vogelstein B., Lengauer C.;
RT   "Characterization of MAD2B and other mitotic spindle checkpoint genes.";
RL   Genomics 58:181-187(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH REV3L.
RX   PubMed=10660610; DOI=10.1074/jbc.275.6.4391;
RA   Murakumo Y., Roth T., Ishii H., Rasio D., Numata S., Croce C.M., Fishel R.;
RT   "A human REV7 homolog that interacts with the polymerase zeta catalytic
RT   subunit hREV3 and the spindle assembly checkpoint protein hMAD2.";
RL   J. Biol. Chem. 275:4391-4397(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum, and Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH FZR1.
RX   PubMed=11459825; DOI=10.1101/gad.897901;
RA   Pfleger C.M., Salic A., Lee E., Kirschner M.W.;
RT   "Inhibition of Cdh1-APC by the MAD2-related protein MAD2L2: a novel
RT   mechanism for regulating Cdh1.";
RL   Genes Dev. 15:1759-1764(2001).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH FZR1 AND CDC20.
RX   PubMed=11459826; DOI=10.1101/gad.898701;
RA   Chen J., Fang G.;
RT   "MAD2B is an inhibitor of the anaphase-promoting complex.";
RL   Genes Dev. 15:1765-1770(2001).
RN   [12]
RP   INTERACTION WITH REV1 AND REV3L, AND HOMOOLIGOMERIZATION.
RX   PubMed=11485998; DOI=10.1074/jbc.m102051200;
RA   Murakumo Y., Ogura Y., Ishii H., Numata S., Ichihara M., Croce C.M.,
RA   Fishel R., Takahashi M.;
RT   "Interactions in the error-prone postreplication repair proteins hREV1,
RT   hREV3, and hREV7.";
RL   J. Biol. Chem. 276:35644-35651(2001).
RN   [13]
RP   INTERACTION WITH PRCC, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11717438; DOI=10.1073/pnas.241304198;
RA   Weterman M.A., van Groningen J.J., Tertoolen L., van Kessel A.G.;
RT   "Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective
RT   t(X;1)-positive renal cell carcinomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:13808-13813(2001).
RN   [14]
RP   FUNCTION IN APC REGULATION, INTERACTION WITH SHIGELLA FLEXNERI IPAB; FZR1
RP   AND CDC20, AND SUBCELLULAR LOCATION.
RX   PubMed=17719540; DOI=10.1016/j.cell.2007.06.043;
RA   Iwai H., Kim M., Yoshikawa Y., Ashida H., Ogawa M., Fujita Y., Muller D.,
RA   Kirikae T., Jackson P.K., Kotani S., Sasakawa C.;
RT   "A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host
RT   cell cycling.";
RL   Cell 130:611-623(2007).
RN   [15]
RP   INTERACTION WITH YY1AP1, AND SUBCELLULAR LOCATION.
RX   PubMed=17541814; DOI=10.1007/s11010-007-9512-8;
RA   Li L., Shi Y., Wu H., Wan B., Li P., Zhou L., Shi H., Huo K.;
RT   "Hepatocellular carcinoma-associated gene 2 interacts with MAD2L2.";
RL   Mol. Cell. Biochem. 304:297-304(2007).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH ELK1 AND JNK KINASES.
RX   PubMed=17296730; DOI=10.1128/mcb.02276-06;
RA   Zhang L., Yang S.H., Sharrocks A.D.;
RT   "Rev7/MAD2B links c-Jun N-terminal protein kinase pathway signaling to
RT   activation of the transcription factor Elk-1.";
RL   Mol. Cell. Biol. 27:2861-2869(2007).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH TCF7L2.
RX   PubMed=19443654; DOI=10.1074/jbc.m109.005017;
RA   Hong C.F., Chou Y.T., Lin Y.S., Wu C.W.;
RT   "MAD2B, a novel TCF4-binding protein, modulates TCF4-mediated epithelial-
RT   mesenchymal transdifferentiation.";
RL   J. Biol. Chem. 284:19613-19622(2009).
RN   [18]
RP   INTERACTION WITH RAN, AND SUBCELLULAR LOCATION.
RX   PubMed=19753112; DOI=10.1371/journal.pone.0007020;
RA   Medendorp K., van Groningen J.J., Vreede L., Hetterschijt L.,
RA   van den Hurk W.H., de Bruijn D.R., Brugmans L., van Kessel A.G.;
RT   "The mitotic arrest deficient protein MAD2B interacts with the small GTPase
RT   RAN throughout the cell cycle.";
RL   PLoS ONE 4:E7020-E7020(2009).
RN   [19]
RP   INTERACTION WITH POGZ.
RX   PubMed=20850016; DOI=10.1016/j.cell.2010.08.020;
RA   Vermeulen M., Eberl H.C., Matarese F., Marks H., Denissov S., Butter F.,
RA   Lee K.K., Olsen J.V., Hyman A.A., Stunnenberg H.G., Mann M.;
RT   "Quantitative interaction proteomics and genome-wide profiling of
RT   epigenetic histone marks and their readers.";
RL   Cell 142:967-980(2010).
RN   [20]
RP   INTERACTION WITH CHAMP1, AND SUBCELLULAR LOCATION.
RX   PubMed=21063390; DOI=10.1038/emboj.2010.276;
RA   Itoh G., Kanno S., Uchida K.S., Chiba S., Sugino S., Watanabe K.,
RA   Mizuno K., Yasui A., Hirota T., Tanaka K.;
RT   "CAMP (C13orf8, ZNF828) is a novel regulator of kinetochore-microtubule
RT   attachment.";
RL   EMBO J. 30:130-144(2011).
RN   [21]
RP   IDENTIFICATION IN POL-ZETA COMPLEX.
RX   PubMed=24449906; DOI=10.1073/pnas.1324001111;
RA   Lee Y.S., Gregory M.T., Yang W.;
RT   "Human Pol zeta purified with accessory subunits is active in translesion
RT   DNA synthesis and complements Pol eta in cisplatin bypass.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2954-2959(2014).
RN   [22]
RP   INVOLVEMENT IN FANCV, VARIANT FANCV GLU-85, AND CHARACTERIZATION OF VARIANT
RP   FANCV GLU-85.
RX   PubMed=27500492; DOI=10.1172/jci88010;
RA   Bluteau D., Masliah-Planchon J., Clairmont C., Rousseau A., Ceccaldi R.,
RA   Dubois d'Enghien C., Bluteau O., Cuccuini W., Gachet S.,
RA   Peffault de Latour R., Leblanc T., Socie G., Baruchel A.,
RA   Stoppa-Lyonnet D., D'Andrea A.D., Soulier J.;
RT   "Biallelic inactivation of REV7 is associated with Fanconi anemia.";
RL   J. Clin. Invest. 126:3580-3584(2016).
RN   [23]
RP   FUNCTION, IDENTIFICATION IN THE SHIELDIN COMPLEX, INTERACTION WITH SHLD2
RP   AND SHLD3, SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=29656893; DOI=10.1016/j.cell.2018.03.050;
RA   Gupta R., Somyajit K., Narita T., Maskey E., Stanlie A., Kremer M.,
RA   Typas D., Lammers M., Mailand N., Nussenzweig A., Lukas J., Choudhary C.;
RT   "DNA repair network analysis reveals shieldin as a key regulator of NHEJ
RT   and PARP inhibitor sensitivity.";
RL   Cell 0:0-0(2018).
RN   [24]
RP   INTERACTION WITH SHLD2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=29789392; DOI=10.15252/embj.201899543;
RA   Tomida J., Takata K.I., Bhetawal S., Person M.D., Chao H.P., Tang D.G.,
RA   Wood R.D.;
RT   "FAM35A associates with REV7 and modulates DNA damage responses of normal
RT   and BRCA1-defective cells.";
RL   EMBO J. 37:0-0(2018).
RN   [25]
RP   INTERACTION WITH ASTE1.
RX   PubMed=34354233; DOI=10.1038/s41556-021-00723-9;
RA   Zhao F., Kim W., Gao H., Liu C., Zhang Y., Chen Y., Deng M., Zhou Q.,
RA   Huang J., Hu Q., Chen S.H., Nowsheen S., Kloeber J.A., Qin B., Yin P.,
RA   Tu X., Guo G., Qin S., Zhang C., Gao M., Luo K., Liu Y., Lou Z., Yuan J.;
RT   "ASTE1 promotes shieldin-complex-mediated DNA repair by attenuating end
RT   resection.";
RL   Nat. Cell Biol. 23:894-904(2021).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH REV3L, FUNCTION,
RP   MUTAGENESIS OF TYR-63; ARG-124; TRP-171; LEU-186; GLN-200 AND TYR-202, AND
RP   INTERACTION WITH REV1.
RX   PubMed=20164194; DOI=10.1074/jbc.m109.092403;
RA   Hara K., Hashimoto H., Murakumo Y., Kobayashi S., Kogame T., Unzai S.,
RA   Akashi S., Takeda S., Shimizu T., Sato M.;
RT   "Crystal structure of human REV7 in complex with a human REV3 fragment and
RT   structural implication of the interaction between DNA polymerase zeta and
RT   REV1.";
RL   J. Biol. Chem. 285:12299-12307(2010).
CC   -!- FUNCTION: Adapter protein able to interact with different proteins and
CC       involved in different biological processes (PubMed:11459825,
CC       PubMed:11459826, PubMed:17296730, PubMed:17719540, PubMed:19443654,
CC       PubMed:29656893). Mediates the interaction between the error-prone DNA
CC       polymerase zeta catalytic subunit REV3L and the inserter polymerase
CC       REV1, thereby mediating the second polymerase switching in translesion
CC       DNA synthesis (PubMed:20164194). Translesion DNA synthesis releases the
CC       replication blockade of replicative polymerases, stalled in presence of
CC       DNA lesions (PubMed:20164194). Component of the shieldin complex, which
CC       plays an important role in repair of DNA double-stranded breaks (DSBs)
CC       (PubMed:29656893). During G1 and S phase of the cell cycle, the complex
CC       functions downstream of TP53BP1 to promote non-homologous end joining
CC       (NHEJ) and suppress DNA end resection (PubMed:29656893). Mediates
CC       various NHEJ-dependent processes including immunoglobulin class-switch
CC       recombination, and fusion of unprotected telomeres (PubMed:29656893).
CC       May also regulate another aspect of cellular response to DNA damage
CC       through regulation of the JNK-mediated phosphorylation and activation
CC       of the transcriptional activator ELK1 (PubMed:17296730). Inhibits the
CC       FZR1- and probably CDC20-mediated activation of the anaphase promoting
CC       complex APC thereby regulating progression through the cell cycle
CC       (PubMed:11459825, PubMed:17719540). Regulates TCF7L2-mediated gene
CC       transcription and may play a role in epithelial-mesenchymal
CC       transdifferentiation (PubMed:19443654). {ECO:0000269|PubMed:11459825,
CC       ECO:0000269|PubMed:11459826, ECO:0000269|PubMed:17296730,
CC       ECO:0000269|PubMed:17719540, ECO:0000269|PubMed:19443654,
CC       ECO:0000269|PubMed:20164194, ECO:0000269|PubMed:29656893}.
CC   -!- SUBUNIT: Homooligomer (Probable). Heterodimer with REV3L
CC       (PubMed:10660610, PubMed:11485998). This dimer forms the minimal DNA
CC       polymerase zeta complex (Pol-zeta2), with REV3L bearing DNA polymerase
CC       catalytic activity, although its activity is very low in this context
CC       (PubMed:11485998). Component of the tetrameric Pol-zeta complex (Pol-
CC       zeta4), which consists of REV3L, MAD2L2, POLD2 and POLD3; Pol-zeta4 is
CC       the fully active form of DNA polymerase zeta (PubMed:24449906).
CC       Component of the shieldin complex, consisting of SHLD1, SHLD2, SHLD3
CC       and MAD2L2/REV7 (PubMed:29656893, PubMed:29789392). Within the complex,
CC       SHLD2 forms a scaffold which interacts with a SHLD3-MAD2L2 subcomplex
CC       via its N-terminus, and with SHLD1 via its C-terminus
CC       (PubMed:29656893). Interacts with REV1 (PubMed:11485998,
CC       PubMed:20164194). Interacts with ADAM9 (PubMed:10527948). Interacts
CC       with CHAMP1 (PubMed:21063390). Interacts with FZR1 (in complex with the
CC       anaphase promoting complex APC) (PubMed:11459825, PubMed:11459826).
CC       Interacts with CDC20; PubMed:11459825 could not detect the interaction
CC       (PubMed:11459826). Interacts with RAN (PubMed:19753112). Interacts with
CC       ELK1; the interaction is direct and recruits MAD2L2 to ELK1-specific
CC       promoters (PubMed:17296730). May interact with the JNK kinases MAPK8
CC       and/or MAPK9 to stimulate ELK1 phosphorylation and transcriptional
CC       activity upon DNA damage (PubMed:17296730). Interacts with TCF7L2;
CC       prevents its binding to promoters and negatively modulates its
CC       transcriptional activity (PubMed:19443654). Interacts with YY1AP1
CC       (PubMed:17541814). Interacts with S.flexneri protein ipaB; prevents the
CC       interaction of MAD2L2 with FZR1 and CDC20 resulting in an activation of
CC       the anaphase-promoting complex APC and a cell cycle arrest
CC       (PubMed:17719540). Interacts with PRCC; the interaction is direct
CC       (PubMed:11717438). Interacts with POGZ (PubMed:20850016). Interacts
CC       with ASTE1 (PubMed:34354233). {ECO:0000269|PubMed:10527948,
CC       ECO:0000269|PubMed:10660610, ECO:0000269|PubMed:11459825,
CC       ECO:0000269|PubMed:11459826, ECO:0000269|PubMed:11485998,
CC       ECO:0000269|PubMed:11717438, ECO:0000269|PubMed:17296730,
CC       ECO:0000269|PubMed:17541814, ECO:0000269|PubMed:17719540,
CC       ECO:0000269|PubMed:19443654, ECO:0000269|PubMed:19753112,
CC       ECO:0000269|PubMed:20164194, ECO:0000269|PubMed:20850016,
CC       ECO:0000269|PubMed:21063390, ECO:0000269|PubMed:24449906,
CC       ECO:0000269|PubMed:29656893, ECO:0000269|PubMed:29789392,
CC       ECO:0000269|PubMed:34354233, ECO:0000305}.
CC   -!- INTERACTION:
CC       Q9UI95; Q13443: ADAM9; NbExp=3; IntAct=EBI-77889, EBI-77903;
CC       Q9UI95; Q13554: CAMK2B; NbExp=3; IntAct=EBI-77889, EBI-1058722;
CC       Q9UI95; Q12834: CDC20; NbExp=2; IntAct=EBI-77889, EBI-367462;
CC       Q9UI95; P30260: CDC27; NbExp=2; IntAct=EBI-77889, EBI-994813;
CC       Q9UI95; Q96JM3: CHAMP1; NbExp=6; IntAct=EBI-77889, EBI-2560420;
CC       Q9UI95; Q9H1P6: CIMIP1; NbExp=3; IntAct=EBI-77889, EBI-12155483;
CC       Q9UI95; O75140-2: DEPDC5; NbExp=3; IntAct=EBI-77889, EBI-12366971;
CC       Q9UI95; P50570-2: DNM2; NbExp=3; IntAct=EBI-77889, EBI-10968534;
CC       Q9UI95; Q9NTX9: FAM217B; NbExp=3; IntAct=EBI-77889, EBI-19153639;
CC       Q9UI95; Q9C0B1-2: FTO; NbExp=3; IntAct=EBI-77889, EBI-18138793;
CC       Q9UI95; Q9UM11: FZR1; NbExp=2; IntAct=EBI-77889, EBI-724997;
CC       Q9UI95; O15499: GSC2; NbExp=3; IntAct=EBI-77889, EBI-19954058;
CC       Q9UI95; Q13422: IKZF1; NbExp=3; IntAct=EBI-77889, EBI-745305;
CC       Q9UI95; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-77889, EBI-747204;
CC       Q9UI95; Q0VD86: INCA1; NbExp=3; IntAct=EBI-77889, EBI-6509505;
CC       Q9UI95; Q7L273: KCTD9; NbExp=3; IntAct=EBI-77889, EBI-4397613;
CC       Q9UI95; O76011: KRT34; NbExp=3; IntAct=EBI-77889, EBI-1047093;
CC       Q9UI95; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-77889, EBI-12516603;
CC       Q9UI95; Q9UPG8: PLAGL2; NbExp=3; IntAct=EBI-77889, EBI-2876622;
CC       Q9UI95; O75688-3: PPM1B; NbExp=3; IntAct=EBI-77889, EBI-17715099;
CC       Q9UI95; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-77889, EBI-1567866;
CC       Q9UI95; Q86YS3: RAB11FIP4; NbExp=3; IntAct=EBI-77889, EBI-949727;
CC       Q9UI95; Q04864: REL; NbExp=3; IntAct=EBI-77889, EBI-307352;
CC       Q9UI95; Q04864-2: REL; NbExp=3; IntAct=EBI-77889, EBI-10829018;
CC       Q9UI95; O60673: REV3L; NbExp=5; IntAct=EBI-77889, EBI-2871302;
CC       Q9UI95; A8K8P3-4: SFI1; NbExp=3; IntAct=EBI-77889, EBI-10321817;
CC       Q9UI95; Q6ZNX1: SHLD3; NbExp=7; IntAct=EBI-77889, EBI-20209073;
CC       Q9UI95; P15884: TCF4; NbExp=3; IntAct=EBI-77889, EBI-533224;
CC       Q9UI95; P15884-3: TCF4; NbExp=3; IntAct=EBI-77889, EBI-13636688;
CC       Q9UI95; Q8TBB0: THAP6; NbExp=3; IntAct=EBI-77889, EBI-3925505;
CC       Q9UI95; P14373: TRIM27; NbExp=3; IntAct=EBI-77889, EBI-719493;
CC       Q9UI95; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-77889, EBI-2130429;
CC       Q9UI95; Q9C029: TRIM7; NbExp=3; IntAct=EBI-77889, EBI-2813981;
CC       Q9UI95; O96006: ZBED1; NbExp=3; IntAct=EBI-77889, EBI-740037;
CC       Q9UI95; Q9H0C1: ZMYND12; NbExp=3; IntAct=EBI-77889, EBI-12030590;
CC       Q9UI95; Q8NB15: ZNF511; NbExp=3; IntAct=EBI-77889, EBI-10269136;
CC       Q9UI95; Q96NG5: ZNF558; NbExp=3; IntAct=EBI-77889, EBI-373363;
CC       Q9UI95; Q8N720: ZNF655; NbExp=3; IntAct=EBI-77889, EBI-625509;
CC       Q9UI95; P18011: sctE; Xeno; NbExp=7; IntAct=EBI-77889, EBI-490239;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11717438,
CC       ECO:0000269|PubMed:17541814, ECO:0000269|PubMed:17719540,
CC       ECO:0000269|PubMed:19753112}. Cytoplasm, cytoskeleton, spindle
CC       {ECO:0000269|PubMed:19753112, ECO:0000269|PubMed:21063390}. Cytoplasm
CC       {ECO:0000269|PubMed:11717438, ECO:0000269|PubMed:17719540}. Chromosome
CC       {ECO:0000269|PubMed:29656893}. Note=Recruited to sites of chromosomal
CC       double-stranded breaks during G1 and S phase of the cell cycle.
CC       {ECO:0000269|PubMed:29656893}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:11717438}.
CC   -!- DISEASE: Fanconi anemia, complementation group V (FANCV) [MIM:617243]:
CC       A disorder affecting all bone marrow elements and resulting in anemia,
CC       leukopenia and thrombopenia. It is associated with cardiac, renal and
CC       limb malformations, dermal pigmentary changes, and a predisposition to
CC       the development of malignancies. At the cellular level it is associated
CC       with hypersensitivity to DNA-damaging agents, chromosomal instability
CC       (increased chromosome breakage) and defective DNA repair.
CC       {ECO:0000269|PubMed:27500492}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF072933; AAD41647.1; -; mRNA.
DR   EMBL; AF080398; AAF20267.1; -; mRNA.
DR   EMBL; AF139365; AAD30290.1; -; mRNA.
DR   EMBL; AF157482; AAF34357.1; -; mRNA.
DR   EMBL; AK027327; BAG51305.1; -; mRNA.
DR   EMBL; AK094316; BAG52858.1; -; mRNA.
DR   EMBL; DQ017900; AAY26393.1; -; Genomic_DNA.
DR   EMBL; AL031731; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471130; EAW71697.1; -; Genomic_DNA.
DR   EMBL; BC015244; AAH15244.1; -; mRNA.
DR   CCDS; CCDS134.1; -.
DR   RefSeq; NP_001120797.1; NM_001127325.2.
DR   RefSeq; NP_006332.3; NM_006341.3.
DR   RefSeq; XP_011538809.1; XM_011540507.1.
DR   RefSeq; XP_047286738.1; XM_047430782.1.
DR   RefSeq; XP_054189822.1; XM_054333847.1.
DR   PDB; 3ABD; X-ray; 1.90 A; A/B=1-211.
DR   PDB; 3ABE; X-ray; 2.60 A; C=1-211.
DR   PDB; 3VU7; X-ray; 2.80 A; C=1-211.
DR   PDB; 4EXT; X-ray; 1.90 A; C=7-209.
DR   PDB; 4GK0; X-ray; 2.70 A; A/B=1-211.
DR   PDB; 4GK5; X-ray; 3.21 A; A/B=1-211.
DR   PDB; 5XPT; X-ray; 2.10 A; A=1-211.
DR   PDB; 5XPU; X-ray; 2.30 A; A=1-211.
DR   PDB; 6BC8; X-ray; 1.68 A; A=1-211.
DR   PDB; 6BCD; X-ray; 1.43 A; A=1-211.
DR   PDB; 6BI7; X-ray; 2.80 A; A/C/E/G=1-211.
DR   PDB; 6K07; X-ray; 2.24 A; A=7-211.
DR   PDB; 6K08; X-ray; 2.31 A; A=7-211.
DR   PDB; 6KEA; X-ray; 2.35 A; A/B/C/D=12-211.
DR   PDB; 6KTO; X-ray; 3.45 A; A/B=1-211.
DR   PDB; 6M7A; X-ray; 1.90 A; A/B=1-208.
DR   PDB; 6M7B; X-ray; 1.77 A; A/B=1-211.
DR   PDB; 6NIF; X-ray; 2.00 A; A=2-211.
DR   PDB; 6VE5; X-ray; 2.00 A; A=1-211.
DR   PDB; 6WS0; X-ray; 2.24 A; CCC=1-211.
DR   PDB; 6WS5; X-ray; 2.47 A; CCC=1-211.
DR   PDB; 6WW9; X-ray; 2.70 A; A/B=2-211.
DR   PDB; 6WWA; X-ray; 3.80 A; A/B/C/D=2-211.
DR   PDB; 7L9P; EM; 3.60 A; G/I/J/K=2-211.
DR   PDBsum; 3ABD; -.
DR   PDBsum; 3ABE; -.
DR   PDBsum; 3VU7; -.
DR   PDBsum; 4EXT; -.
DR   PDBsum; 4GK0; -.
DR   PDBsum; 4GK5; -.
DR   PDBsum; 5XPT; -.
DR   PDBsum; 5XPU; -.
DR   PDBsum; 6BC8; -.
DR   PDBsum; 6BCD; -.
DR   PDBsum; 6BI7; -.
DR   PDBsum; 6K07; -.
DR   PDBsum; 6K08; -.
DR   PDBsum; 6KEA; -.
DR   PDBsum; 6KTO; -.
DR   PDBsum; 6M7A; -.
DR   PDBsum; 6M7B; -.
DR   PDBsum; 6NIF; -.
DR   PDBsum; 6VE5; -.
DR   PDBsum; 6WS0; -.
DR   PDBsum; 6WS5; -.
DR   PDBsum; 6WW9; -.
DR   PDBsum; 6WWA; -.
DR   PDBsum; 7L9P; -.
DR   AlphaFoldDB; Q9UI95; -.
DR   EMDB; EMD-23244; -.
DR   SASBDB; Q9UI95; -.
DR   SMR; Q9UI95; -.
DR   BioGRID; 115722; 334.
DR   ComplexPortal; CPX-3481; Shieldin complex.
DR   ComplexPortal; CPX-994; DNA polymerase zeta complex.
DR   CORUM; Q9UI95; -.
DR   FunCoup; Q9UI95; 1335.
DR   IntAct; Q9UI95; 178.
DR   MINT; Q9UI95; -.
DR   STRING; 9606.ENSP00000235310; -.
DR   ChEMBL; CHEMBL4524021; -.
DR   iPTMnet; Q9UI95; -.
DR   PhosphoSitePlus; Q9UI95; -.
DR   BioMuta; MAD2L2; -.
DR   jPOST; Q9UI95; -.
DR   MassIVE; Q9UI95; -.
DR   PaxDb; 9606-ENSP00000235310; -.
DR   PeptideAtlas; Q9UI95; -.
DR   ProteomicsDB; 84481; -.
DR   Pumba; Q9UI95; -.
DR   TopDownProteomics; Q9UI95; -.
DR   Antibodypedia; 3766; 204 antibodies from 31 providers.
DR   DNASU; 10459; -.
DR   Ensembl; ENST00000235310.7; ENSP00000235310.2; ENSG00000116670.17.
DR   Ensembl; ENST00000376667.7; ENSP00000365855.3; ENSG00000116670.17.
DR   Ensembl; ENST00000376692.9; ENSP00000365882.4; ENSG00000116670.17.
DR   Ensembl; ENST00000456915.2; ENSP00000400982.2; ENSG00000116670.17.
DR   Ensembl; ENST00000717649.1; ENSP00000520633.1; ENSG00000116670.17.
DR   GeneID; 10459; -.
DR   KEGG; hsa:10459; -.
DR   MANE-Select; ENST00000376692.9; ENSP00000365882.4; NM_006341.4; NP_006332.3.
DR   UCSC; uc001asp.4; human.
DR   AGR; HGNC:6764; -.
DR   CTD; 10459; -.
DR   DisGeNET; 10459; -.
DR   GeneCards; MAD2L2; -.
DR   GeneReviews; MAD2L2; -.
DR   HGNC; HGNC:6764; MAD2L2.
DR   HPA; ENSG00000116670; Low tissue specificity.
DR   MalaCards; MAD2L2; -.
DR   MIM; 604094; gene.
DR   MIM; 617243; phenotype.
DR   OpenTargets; ENSG00000116670; -.
DR   Orphanet; 84; Fanconi anemia.
DR   VEuPathDB; HostDB:ENSG00000116670; -.
DR   eggNOG; KOG3186; Eukaryota.
DR   GeneTree; ENSGT00940000153395; -.
DR   InParanoid; Q9UI95; -.
DR   OMA; CEDFPWI; -.
DR   OrthoDB; 21254at2759; -.
DR   PAN-GO; Q9UI95; 1 GO annotation based on evolutionary models.
DR   PhylomeDB; Q9UI95; -.
DR   PathwayCommons; Q9UI95; -.
DR   Reactome; R-HSA-110312; Translesion synthesis by REV1.
DR   Reactome; R-HSA-5655862; Translesion synthesis by POLK.
DR   Reactome; R-HSA-5656121; Translesion synthesis by POLI.
DR   SignaLink; Q9UI95; -.
DR   SIGNOR; Q9UI95; -.
DR   BioGRID-ORCS; 10459; 716 hits in 1167 CRISPR screens.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   ChiTaRS; MAD2L2; human.
DR   EvolutionaryTrace; Q9UI95; -.
DR   GeneWiki; MAD2L2; -.
DR   GenomeRNAi; 10459; -.
DR   Pharos; Q9UI95; Tbio.
DR   PRO; PR:Q9UI95; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9UI95; protein.
DR   Bgee; ENSG00000116670; Expressed in ganglionic eminence and 164 other cell types or tissues.
DR   ExpressionAtlas; Q9UI95; baseline and differential.
DR   GO; GO:0000785; C:chromatin; NAS:ComplexPortal.
DR   GO; GO:0005694; C:chromosome; IC:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0035861; C:site of double-strand break; NAS:ComplexPortal.
DR   GO; GO:0005819; C:spindle; IDA:UniProtKB.
DR   GO; GO:0016035; C:zeta DNA polymerase complex; IDA:UniProtKB.
DR   GO; GO:0008432; F:JUN kinase binding; IDA:UniProtKB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0003714; F:transcription corepressor activity; IMP:BHF-UCL.
DR   GO; GO:0007015; P:actin filament organization; IMP:BHF-UCL.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0042772; P:DNA damage response, signal transduction resulting in transcription; IDA:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IGI:UniProtKB.
DR   GO; GO:0042276; P:error-prone translesion synthesis; IDA:ComplexPortal.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint signaling; TAS:ProtInc.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; IMP:BHF-UCL.
DR   GO; GO:2000042; P:negative regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0010944; P:negative regulation of transcription by competitive promoter binding; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:1904667; P:negative regulation of ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:2001034; P:positive regulation of double-strand break repair via nonhomologous end joining; IDA:UniProtKB.
DR   GO; GO:0045830; P:positive regulation of isotype switching; IDA:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IGI:UniProtKB.
DR   GO; GO:0002208; P:somatic diversification of immunoglobulins involved in immune response; NAS:ComplexPortal.
DR   GO; GO:0043247; P:telomere maintenance in response to DNA damage; NAS:ComplexPortal.
DR   FunFam; 3.30.900.10:FF:000003; Mitotic spindle assembly checkpoint protein MAD2B; 1.
DR   Gene3D; 3.30.900.10; HORMA domain; 1.
DR   IDEAL; IID00285; -.
DR   InterPro; IPR003511; HORMA_dom.
DR   InterPro; IPR036570; HORMA_dom_sf.
DR   InterPro; IPR045091; Mad2-like.
DR   PANTHER; PTHR11842; MITOTIC SPINDLE ASSEMBLY CHECKPOINT PROTEIN MAD2; 1.
DR   PANTHER; PTHR11842:SF15; MITOTIC SPINDLE ASSEMBLY CHECKPOINT PROTEIN MAD2B; 1.
DR   Pfam; PF02301; HORMA; 1.
DR   SUPFAM; SSF56019; The spindle assembly checkpoint protein mad2; 1.
DR   PROSITE; PS50815; HORMA; 1.
DR   neXtProt; NX_Q9UI95; -.
DR   PharmGKB; PA398; -.
DR   TreeFam; TF101085; -.
PE   1: Evidence at protein level;
KW   3D-structure; Cell cycle; Cell division; Chromosome; Cytoplasm;
KW   Cytoskeleton; Disease variant; DNA damage; DNA repair; Fanconi anemia;
KW   Mitosis; Nucleus; Proteomics identification; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN           1..211
FT                   /note="Mitotic spindle assembly checkpoint protein MAD2B"
FT                   /id="PRO_0000126119"
FT   DOMAIN          13..203
FT                   /note="HORMA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00109"
FT   REGION          21..155
FT                   /note="Mediates interaction with REV1 and REV3L and
FT                   homodimerization"
FT   REGION          150..211
FT                   /note="Mediates interaction with ipaB"
FT   VARIANT         85
FT                   /note="V -> E (in FANCV; drastically reduced protein
FT                   abundance; dbSNP:rs1057517674)"
FT                   /evidence="ECO:0000269|PubMed:27500492"
FT                   /id="VAR_077981"
FT   MUTAGEN         63
FT                   /note="Y->A: Alters interaction with REV3L. Loss of
FT                   interaction with REV3L; when associated with A-171."
FT                   /evidence="ECO:0000269|PubMed:20164194"
FT   MUTAGEN         124
FT                   /note="R->A: Induces structural changes that increase
FT                   affinity for REV3L and REV1. No effect on interaction with
FT                   REV1; when associated with A-171."
FT                   /evidence="ECO:0000269|PubMed:20164194"
FT   MUTAGEN         171
FT                   /note="W->A: Alters interaction with REV3L and REV1. Loss
FT                   of interaction with REV3L; when associated with A-63. No
FT                   effect on interaction with REV1; when associated with
FT                   A-124."
FT                   /evidence="ECO:0000269|PubMed:20164194"
FT   MUTAGEN         186
FT                   /note="L->A: Significantly prevents interaction with REV1;
FT                   no effect on interaction with REV3L."
FT                   /evidence="ECO:0000269|PubMed:20164194"
FT   MUTAGEN         200
FT                   /note="Q->A: Significantly prevents interaction with REV1;
FT                   no effect on interaction with REV3L."
FT                   /evidence="ECO:0000269|PubMed:20164194"
FT   MUTAGEN         202
FT                   /note="Y->A: Significantly prevents interaction with REV1;
FT                   no effect on interaction with REV3L."
FT                   /evidence="ECO:0000269|PubMed:20164194"
FT   CONFLICT        17
FT                   /note="D -> A (in Ref. 3; AAD30290)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="E -> D (in Ref. 2; AAF20267)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        199
FT                   /note="M -> V (in Ref. 2; AAF20267)"
FT                   /evidence="ECO:0000305"
FT   HELIX           6..8
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           10..12
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           13..33
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           39..41
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          42..47
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          50..55
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           58..76
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          80..88
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          90..92
FT                   /evidence="ECO:0007829|PDB:3ABE"
FT   STRAND          94..103
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   TURN            106..111
FT                   /evidence="ECO:0007829|PDB:5XPT"
FT   STRAND          112..114
FT                   /evidence="ECO:0007829|PDB:6M7B"
FT   TURN            115..118
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           119..131
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           133..135
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          145..155
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           156..159
FT                   /evidence="ECO:0007829|PDB:6M7B"
FT   STRAND          162..166
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          169..173
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   HELIX           176..179
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          185..196
FT                   /evidence="ECO:0007829|PDB:6BCD"
FT   STRAND          198..205
FT                   /evidence="ECO:0007829|PDB:6BCD"
SQ   SEQUENCE   211 AA;  24334 MW;  1DE6353EF7D650B9 CRC64;
     MTTLTRQDLN FGQVVADVLC EFLEVAVHLI LYVREVYPVG IFQKRKKYNV PVQMSCHPEL
     NQYIQDTLHC VKPLLEKNDV EKVVVVILDK EHRPVEKFVF EITQPPLLSI SSDSLLSHVE
     QLLRAFILKI SVCDAVLDHN PPGCTFTVLV HTREAATRNM EKIQVIKDFP WILADEQDVH
     MHDPRLIPLK TMTSDILKMQ LYVEERAHKG S
//
